Related Experiment Videos
Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment
G F Hofbauer1, B Kessler, W Kempf
1Department of Dermatology, University Hospital, Zürich, Switzerland.
Summary
Borrelia burgdorferi infection may be linked to cutaneous B-cell lymphoma. Antibiotic treatment led to remission in a patient with elevated B. burgdorferi titers, suggesting a potential therapeutic target.
Area of Science:
- Dermatology
- Infectious Diseases
- Oncology
Background:
- Cutaneous B-cell lymphoma (CBCL) is a type of non-Hodgkin lymphoma affecting the skin.
- Borrelia burgdorferi, the bacterium causing Lyme disease, has been investigated for its potential role in certain lymphomas.
- Understanding the interplay between infectious agents and lymphomagenesis is crucial for effective treatment strategies.
Observation:
- A case study involving a patient with multilesional primary cutaneous large B-cell lymphoma (pcLBCL) was analyzed.
- The patient presented with elevated titers of Borrelia burgdorferi antibodies.
- No evidence of extracutaneous spread of the lymphoma was detected at the time of diagnosis.
Findings:
- Following a course of antibiotic therapy targeting Borrelia burgdorferi, the patient achieved clinical remission of the lymphoma.
- Concurrently, a significant decrease in Borrelia burgdorferi antibody titers was observed post-treatment.
- These results suggest a potential association between Borrelia burgdorferi infection and this specific presentation of pcLBCL.
Implications:
- This case highlights the importance of considering infectious triggers, such as Borrelia burgdorferi, in the differential diagnosis of cutaneous B-cell lymphoma.
- Antibiotic therapy may represent a viable treatment option for pcLBCL in patients with evidence of Borrelia burgdorferi infection.
- Further research is warranted to elucidate the precise mechanisms underlying this association and to validate antibiotic treatment in larger cohorts.